PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1618189
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1618189
Prostate Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Prostate Cancer Diagnostics Market was valued at USD 4.5 billion in 2023 and is projected to grow at a CAGR of 10.5% from 2024 to 2032. This expansion is driven by the rising incidence of prostate cancer, increasing awareness about risk factors, technological advancements, and significant investments in innovative diagnostic methods. These combined factors are pushing the market forward. As prostate cancer becomes more prevalent, especially among aging populations, there is a growing need for timely and accurate diagnostic tools. Public health campaigns and awareness efforts encourage men to undergo regular screenings, further propelling market demand.
Additionally, the focus on early detection and personalized treatment options is boosting the adoption of advanced diagnostic technologies. The market is segmented by test type into diagnostic tests and imaging tests, with diagnostic tests leading the way. In 2023, diagnostic tests generated USD 2.9 billion in revenue, largely due to their critical role in early detection. The PSA (prostate-specific antigen) test is particularly crucial, as it measures the level of this cancer-related protein in the blood.
PSA testing is commonly used in routine health checks, particularly for men over 50, and with advancements in testing sensitivity, these diagnostics continue to play a vital role in cancer detection. In terms of cancer types, the prostatic adenocarcinoma, which accounts for over 95% of prostate cancer cases, generated the highest revenue at USD 4.1 billion in 2023. This type of cancer, affecting the gland cells of the prostate, is the most prevalent, driving the need for specialized diagnostic tools. The North America market, which accounted for USD 1.8 billion in revenue in 2023, is anticipated to grow significantly at a CAGR of 9.9% through 2032. This growth is fueled by a combination of high awareness levels, advanced healthcare infrastructure, and regular screening programs. Additionally, regulatory bodies such as the FDA support the rapid adoption of innovative diagnostic solutions, including liquid biopsy and genetic testing, further enhancing the market's growth potential.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $4.5 Billion |
| Forecast Value | $11.1 Billion |
| CAGR | 10.5% |
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of prostate cancer
- 3.2.1.2 Technological advancement
- 3.2.1.3 Surging awareness and screening initiatives
- 3.2.1.4 Increasing popularity of prostate cancer diagnostic tests
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Lack of skilled professionals
- 3.2.2.2 Stringent regulations
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Reimbursement scenario
- 3.7 Key market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
- 3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Diagnostics tests
- 5.2.1 PSA
- 5.2.2 Prostate biopsy
- 5.2.3 Molecular/ genomic test
- 5.2.4 Other diagnostics tests
- 5.3 Imaging tests
- 5.3.1 Transrectal ultrasound (TRUS)
- 5.3.2 MRI
- 5.3.3 CT Scan
- 5.3.4 Other imaging tests
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Prostatic adenocarcinoma
- 6.3 Small cell carcinoma
- 6.4 Other prostate cancer types
Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic laboratories
- 7.4 Cancer research institutes
- 7.5 Other end use
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Poland
- 8.3.7 Sweden
- 8.3.8 Netherlands
- 8.3.9 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Philippines
- 8.4.8 Vietnam
- 8.4.9 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Colombia
- 8.5.5 Chile
- 8.5.6 Peru
- 8.5.7 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Turkey
- 8.6.5 Iran
- 8.6.6 Israel
- 8.6.7 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Abbott Laboratories
- 9.2 AdvaCare Pharma
- 9.3 Beckman Coulter, Inc. (Danaher Corporation)
- 9.4 Becton, Dickinson and Company
- 9.5 BIOMERIEUX
- 9.6 F. Hoffmann-La Roche Ltd.
- 9.7 FUJIFILM Holdings Corporation
- 9.8 GE Healthcare Technologies Inc.
- 9.9 Glycanostcs Ltd.
- 9.10 Healgen
- 9.11 KOELIS
- 9.12 Koninklijke Philips N.V.
- 9.13 Metamark Genetics, Inc.
- 9.14 miR Scientific
- 9.15 Myriad Genetics, Inc.
- 9.16 Proteomedix
- 9.17 Siemens Healthineers AG
- 9.18 Veracyte
